Next-generation AI-powered digital biomarkers for cardiology and clinical research
arterioscope is a med-tech spin-off from Graz University of Technology developing the next generation of non-invasive digital biomarkers for cardiovascular health. Our platform extracts molecular-level biomarker signals — starting with NT-proBNP — directly from everyday biosignals such as ECG and PPG.
Originally initiated as a strategic research collaboration between TU Graz, clinical partners, and industry, arterioscope has evolved into a digital biomarker platform designed for biotech and pharmaceutical companies, OEMs, and later healthcare providers.
Our Solution
arterioscope builds AI models that translate biosignals into clinically meaningful biomarkers that traditionally require blood draws. By training on large, paired datasets, our proprietary algorithms enable:
- Non-invasive estimation of key cardiovascular biomarkers
- Early detection of heart failure and cardiometabolic risk
- Improved patient stratification in clinical trials
- Continuous, scalable monitoring during drug development or device use
This technology allows biotech and pharma companies to introduce exploratory endpoints, reduce trial variability, and gain deeper mechanistic insight into patient response — even in small cohorts.
Mission
Our mission is to become the global platform for non-invasive biomarker diagnostics.
We aim to make molecular-level insights accessible without a single drop of blood — empowering earlier detection, personalized therapy decisions, and more efficient cardiovascular drug development.
Team:
Hermann Moser, Co-Founder & CEO / Vahid Badeli, Co-Founder & CTO / Sascha Ranftl, Co-Founder & CSO
Social Media Channels